BioMarin Pharmaceutical Inc. BMRN announced an update on its Roctavian business to focus commercial operations on three markets: the U.S., Germany and Italy. These markets are where the medicine is approved and reimbursed as a severe hemophilia A treatment. The company will adjust its Roctavian efforts and reduce additional investments in development and manufacturing. BioMarin anticipates reducing annual direct Roctavian expenses to approximately $60 million beginning in 2025. The company has already begun ...